1. Large Between-Patient Variability in eGFR Decline before Clinical Trial Enrollment and Impact on Atrasentan’s Efficacy
- Author
-
Hans-Henrik Parving, José Luis Górriz, Sydney C.W. Tang, Michele Provenzano, Luca De Nicola, Simke W. Waijer, Dick de Zeeuw, Julio Pascual, Christoph Wanner, Robert S. Busch, Ron T. Gansevoort, Di Xie, Fan Fan Hou, Sieta T. de Vries, Pablo E. Pergola, Philippe Zaoui, Gozewijn D. Laverman, Hiddo J.L. Heerspink, Waijer, S. W., de Vries, S. T., Busch, R., Xie, D., Gansevoort, R. T., Hou, F. F., Gorriz, J. L., Laverman, G. D., de Nicola, L., Pascual, J., Provenzano, M., Pergola, P. E., Tang, S. C. W., Wanner, C., Zaoui, P., Parving, H. -H., de Zeeuw, D., Heerspink, H. J. L., Cardiovascular Centre (CVC), Groningen Kidney Center (GKC), Real World Studies in PharmacoEpidemiology, -Genetics, -Economics and -Therapy (PEGET), and Biomedical Signals and Systems
- Subjects
Oncology ,medicine.medical_specialty ,MEDLINE ,eGFR decline ,Type 2 diabetes ,Egfr decline ,endothelin receptor antagonist ,law.invention ,Randomized controlled trial ,law ,Internal medicine ,Post-hoc analysis ,medicine ,business.industry ,Endothelin receptor antagonist ,Atrasentan ,22/2 OA procedure ,General Medicine ,medicine.disease ,Clinical trial ,Nephrology ,randomized controlled trial ,type 2 diabetes ,business ,chronic kidney disease ,medicine.drug - Abstract
n/a.
- Published
- 2021
- Full Text
- View/download PDF